I guess it depends on trading strategy and foresight as far as expectations go with the compounding pharmacy industry. If someone is trading this, then I could recognize the Diaprim alternative announcement as a "pump". But then there are traders and then there are investors; 2 different animals.
I think Mark Baum and Imprimis is seizing an opportunity to answer an unmet need to offer a compound based on a generic drug's active ingredient and deliver it to the patient at an affordable cost. Their operations are highly regulated and have to meet strict standards but Imprimis is a pharmacy, so they have the ability to turn the prescriptions out quickly. Baum recently stated they are creating a program called "Imprimis Cares" to identify other generic drugs that have become unaffordable due to price gouging. I've read that they have been inundated with calls from doctors and nurses suggesting other compounds to meet the patients needs and bring their patients' healthcare costs down.
I broke one of my trading rules - never rush in until after 10:15 - 10:45 when the houses are done closing short positions. And I think this suffered a bear raid so that bigger money can grab as many shares as possible at lower prices, hence the pps recovery late in the day. I'm in at 7.75 so I feel you.
However, if this is a white knight / disruptive technology storyline that can be expanded to meet more and more patient needs, This is a buy and hold through the 2016 elections considering how few shares are available and affordable prescription drugs are an issue that affects a large part of the population. Tiny floats are sometimes epic. Most people were not made aware of the story until late Friday when larger publications began running the piece. Every story I read has to explain in detail how a compounding pharmacy operates, so this could be in its infancy even though they are operating like a 1950's apothecary with a mortar and pestle - but on a larger scale.
